Company attributes
Other attributes
MiRXES is a Singapore-headquartered biotech firm with R&D, manufacturing, and clinical lab operations in Singapore, USA, Japan, and China. A molecular diagnostics company, it specializes in microRNA technologies and the development, manufacturing, and provision of diagnostic test kits and clinical services.
MiRXES offers blood tests which use microRNAs - small strands of genetic code found in the bloodstream - as cancer markers. Blood-based microRNAs have, within their genetic code, information about the cancer profiles they carry and therefore have potential to work as a signaler for the presence of different types of cancer.
In February 2020, MiRXES won the rights to manufacture and commercialize the Sars-CoV-2 diagnostic test kits for the novel coronavirus COVID-19. The diagnostic test kit was developed by Singapore's Agency for Science, Technology and Research (A*Star) and Tan Tock Seng Hospital, and has received provisional authorization from the Health Sciences Authority.MiRXES is backed by Singapore-based venture capital firm Venturecraft, which invests in global growth-stage and late-stage ventures in medtech, biotech, and digital health.
